KR970704447A - 푸시드산 정제의 제조방법(Preparation of fusidic acid tablets) - Google Patents

푸시드산 정제의 제조방법(Preparation of fusidic acid tablets) Download PDF

Info

Publication number
KR970704447A
KR970704447A KR1019970700432A KR19970700432A KR970704447A KR 970704447 A KR970704447 A KR 970704447A KR 1019970700432 A KR1019970700432 A KR 1019970700432A KR 19970700432 A KR19970700432 A KR 19970700432A KR 970704447 A KR970704447 A KR 970704447A
Authority
KR
South Korea
Prior art keywords
sodium
bulk density
salt
preparation
tablet
Prior art date
Application number
KR1019970700432A
Other languages
English (en)
Other versions
KR100358614B1 (ko
Inventor
에릭 프레벤 라스무쎈
Original Assignee
룬딩 에른스트
레오 파마슈티칼즈 프로덕츠 리미티드 에이/에스(뢰벤스 케미스케 파브릭 프로둑티온즈악티젤스카브)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 룬딩 에른스트, 레오 파마슈티칼즈 프로덕츠 리미티드 에이/에스(뢰벤스 케미스케 파브릭 프로둑티온즈악티젤스카브) filed Critical 룬딩 에른스트
Publication of KR970704447A publication Critical patent/KR970704447A/ko
Application granted granted Critical
Publication of KR100358614B1 publication Critical patent/KR100358614B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Formation And Processing Of Food Products (AREA)

Abstract

본 발명은 건식 분말성 형태의 활성 성분을 롤러 압축기에서 압축시키고, 이어서 정제용 과립이 형성되도록 하기 위하여 크기를 축소시키는, 장용성 코팅을 하지 않은 푸시드산 나트륨 염 정제의 제조방법에 관한 것이다.

Description

푸시드산 정제의 제조방법(Preparation of fusidic acid tablets)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 건식 분말성 푸시드산 나트륨 염을 롤러 압축기에서 압축시키고 이렇게 하여 수득한 압축 물질의 크기를 줄어 0.45내지 0.9g/㎤ 범위의 부피 밀도를 갖는 과립을 형성시킨 다음, 정제로 제형화시킴을 포함하는, 장용성 코팅을 하지 않은 푸시드산 나트륨 염 정제(tablet)의 제조방법.
  2. 제1항에 있어서, 과립의 입자 크기가 100 내지 300㎛인 방법.
  3. 제1항 또는 제2항에 있어서, 과립의 부피 밀도가 0.5내지 0.7g/㎤인 방법.
  4. 제1항 내지 제3항 중의 어느 한 항에 있어서, 분말성 푸시드산 나트륨 염을 α-토코페롤로 코팅하는 방법.
  5. 제1항 내지 제4항 중의 어느 한 항에 있어서, 제조된 정제를 필름 코팅하는 방법.
  6. 0.45 내지 0.9g/㎤의 부피 밀도를 갖는, 압축한 분말성 푸시드산 나트륨 염의 건식 과립으로부터 형성된 장용성 코팅을 하지 않은 푸시드산 나트륨 염의 정제.
  7. 압축한 분말성 푸시드산 나트륨 염을 포함하고 0.45 내지 0.9g/㎤의 부피 밀도를 갖는, 제6항에 따른 정제의 제조용 과립.
  8. 0.45내지 0.9g/㎤의 부피 밀도를 갖는 압축한 분말성 푸시드산 나트륨 염을 정제로 제형화시킴을 포함하는, 장용성 코팅을 하지 않은 푸시드산 나트륨 염 정제의 제조방법.
  9. 제6항, 제7항 또는 제8항에 있어서, 부피 밀도가 0.5 내지 0.7g/㎤인 정제, 과립 또는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970700432A 1994-07-26 1995-07-21 푸시드산정제의제조방법 KR100358614B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9415048.9 1994-07-26
GB9415048A GB9415048D0 (en) 1994-07-26 1994-07-26 Tablet

Publications (2)

Publication Number Publication Date
KR970704447A true KR970704447A (ko) 1997-09-06
KR100358614B1 KR100358614B1 (ko) 2003-01-10

Family

ID=10758888

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700432A KR100358614B1 (ko) 1994-07-26 1995-07-21 푸시드산정제의제조방법

Country Status (20)

Country Link
EP (1) EP0773783B1 (ko)
JP (1) JP3853358B2 (ko)
KR (1) KR100358614B1 (ko)
CN (1) CN1070703C (ko)
AT (1) ATE209496T1 (ko)
AU (1) AU681980B2 (ko)
CA (1) CA2193235C (ko)
CZ (1) CZ286197B6 (ko)
DE (1) DE69524226T2 (ko)
DK (1) DK0773783T3 (ko)
ES (1) ES2163521T3 (ko)
FI (1) FI117666B (ko)
GB (1) GB9415048D0 (ko)
HU (1) HU221483B (ko)
NZ (1) NZ290806A (ko)
PL (1) PL180935B1 (ko)
PT (1) PT773783E (ko)
RO (1) RO118633B1 (ko)
RU (1) RU2140272C1 (ko)
WO (1) WO1996003128A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518291A (ja) * 1997-08-20 2002-06-25 フイズ テクノロジーズ リミテッド 錠剤組成物の流動性及び圧縮性の改善方法
WO2007051468A2 (en) 2005-10-31 2007-05-10 Leo Pharma A/S Preparation of an antibiotic crystalline fusidic acid
FR2895908B1 (fr) * 2006-01-12 2008-03-28 France Etat Procede de fabrication d'une forme pharmaceutique de phosphate d'oseltamivir
JP5249568B2 (ja) * 2007-12-06 2013-07-31 旭化成ケミカルズ株式会社 成形用粉末、およびこれを用いた圧縮成形組成物、ならびに成形用粉末の製造方法
DE102008051783A1 (de) * 2008-10-17 2010-04-22 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Valsartan enthaltende Tablette
EP2382968A1 (en) 2010-03-26 2011-11-02 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Particle size distribution of fusidic acid granules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7411402A (nl) * 1973-09-13 1975-03-17 Leo Pharm Prod Ltd Werkwijze voor het bereiden van een middel tegen arthritis.
EP0300073A1 (en) * 1987-07-22 1989-01-25 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Use of fusidic acid in the treatment of aids-related complex and full-blown aids

Also Published As

Publication number Publication date
HU221483B (en) 2002-10-28
CA2193235A1 (en) 1996-02-08
CZ286197B6 (cs) 2000-02-16
PT773783E (pt) 2002-04-29
CA2193235C (en) 2008-03-18
NZ290806A (en) 1998-01-26
RO118633B1 (ro) 2003-08-29
FI965214A (fi) 1996-12-27
EP0773783A1 (en) 1997-05-21
PL180935B1 (pl) 2001-05-31
CN1070703C (zh) 2001-09-12
HU9700217D0 (en) 1997-04-28
ES2163521T3 (es) 2002-02-01
ATE209496T1 (de) 2001-12-15
RU2140272C1 (ru) 1999-10-27
HUT76836A (en) 1997-11-28
AU3164495A (en) 1996-02-22
WO1996003128A1 (en) 1996-02-08
CZ22997A3 (en) 1997-04-16
FI117666B (fi) 2007-01-15
DE69524226D1 (de) 2002-01-10
GB9415048D0 (en) 1994-09-14
DE69524226T2 (de) 2002-06-27
JP3853358B2 (ja) 2006-12-06
FI965214A0 (fi) 1996-12-27
EP0773783B1 (en) 2001-11-28
JPH10502937A (ja) 1998-03-17
CN1154066A (zh) 1997-07-09
DK0773783T3 (da) 2002-04-02
AU681980B2 (en) 1997-09-11
KR100358614B1 (ko) 2003-01-10
PL318261A1 (en) 1997-05-26

Similar Documents

Publication Publication Date Title
TR199901804T2 (xx) Oksakarbazepin filmi kaplanm�� tabletler
AU6504686A (en) Sustained release compositions comprising hydroxypropyl cellulose ethers
UY23958A1 (es) Procedimiento para la preparación de formas de dosificación de liberación controlada de azitromicina
AU578577B2 (en) Devices for the controlled release of active substances, as well as process for the preparation thereof
GB2186485B (en) Slow release formulation
ES8303088A1 (es) Procedimiento para la obtencion de una forma retardada de medicamento granulado.
DK0525389T3 (da) Fremgangsmåde til fremstilling af mekanisk stabile, let henfaldende tabletter af formlegemer, som indeholder aktivt stof
AU5462998A (en) Co-processed microcrystalline cellulose and calcium carbonate
CA2327655A1 (en) Tablet production method and tablet
AU552861B2 (en) Quick disintigrating tablets with delayed release release pharmacological action
PL346714A1 (en) Method for preparing novel fenofibrate galenic formulations, galenic formulations obtained and applications
KR970704447A (ko) 푸시드산 정제의 제조방법(Preparation of fusidic acid tablets)
GB1287431A (en) Improvements in pharmaceutical formulations
AU1434700A (en) Dry powder pharmaceutical formulation
CN1444852A (zh) 强力消毒精颗粒剂
CA2185242A1 (en) Sustained release tablet containing diclofenac-na
JP2000016936A (ja) ロキソプロフェン・ナトリウム含有固形製剤
TR200102802T2 (tr) Tabletlerin direk kompresyonla üretiminde, yüksek L-karnitin-alkanoil L-karnitinli granülat
FR2106566A1 (en) Tabletting active materials - by compressing encapsulated particles
WO1998056359A3 (de) Zusammensetzungen, die die wirkstofffreisetzung verzögern
RU97102767A (ru) Приготовление таблеток фузидовой кислоты
EP1013271A3 (en) Nimodipine tablets
KR880009638A (ko) 피부 외용제 배합용 과립상 물질의 제조방법
KR960030782A (ko) 수표면 살포용 살충제 조성물 및 이의 제조방법
ES2018735A6 (es) Procedimiento para la operacion de un producto potabilizador del agua.

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120926

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20130930

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20140925

Year of fee payment: 13

EXPY Expiration of term